Germany, BeNeLuxBelgiumNetherlandsLuxembourg

Ablynx extends Boehringer deal

24.09.2007

Ghent – Boehringer Ingelheim and Ablynx NV have extended their large research and development deal. In January, the Belgian biopharmaceutical company and the German pharma firm signed an exclusive global collaboration potentially worth €200 million to discover and develop nanobody-based treatments for Alzheimer’s disease. Under the extended alliance, the two partners plan to develop nanobodies against ten targets supported by Boehringer. Nanobodies are single-domain antibody fragments derived from camelid antibodies that lack a light chain.
Boehringer will pay €15 million up front for an as-yet undecided stake in Ablynx, the first time the latter has taken such dilutive financing from a partner. Boehringer also will pay up to €60 million in research funding and milestones and up to €125 million in development milestones, plus royalties. Dr Andreas Barner, Vice-Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine of Boehringer Ingelheim said: “We hope that this broad collaboration will lead to breakthroughs for patients suffering from diseases which cannot be adequately treated at present.”

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Mechelen - Galapagos NV confirms its status as one of Europe best drug discovery companies. The Belgian biotech received €4 million as the first milestone payments from French Servier for the discovery of new targets for...

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/ablynx-extends-boehringer-deal.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%
  • MORPHOSYS75.99 EUR4.89%

FLOP

  • EPIGENOMICS4.15 EUR-4.38%
  • EVONIK26.20 EUR-2.42%
  • PAION2.80 EUR-2.10%

TOP

  • BIOFRONTERA2.82 EUR28.2%
  • HBM91.50 CHF8.6%
  • EPIGENOMICS4.15 EUR8.4%

FLOP

  • MAGFORCE5.55 EUR-19.6%
  • CO.DON2.65 EUR-15.6%
  • PAION2.80 EUR-13.0%

TOP

  • SANTHERA89.00 CHF2318.5%
  • CO.DON2.65 EUR167.7%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 30.10.2014


Current issue

All issues

Product of the week

Products